Lv2
200 积分 2024-04-09 加入
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
2小时前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
2小时前
已关闭
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
4个月前
已完结
Secukinumab: First Global Approval
5个月前
已完结
Mirikizumab: First Approval
5个月前
已完结
Therapeutic monoclonal antibody concentration monitoring: free or total?
5个月前
已完结
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
6个月前
已完结
CD38 — a new target in renal immune disease
6个月前
已完结
Tarlatamab: First Approval
6个月前
已完结
Margetuximab: First Approval
6个月前
已完结
皖公网安备34019202002308
